

Measure Title: Percentage of Patients who Died with Cancer with More Than One Emergency Department and/or Observation Visit in the Last 30 Days of Life (<i>lower score – better</i>)	
Measure Description:	Percentage of patients, aged 18 years and older, who died with cancer with more than one emergency department and/or observation visit in the last 30 days of life
Denominator	Patients, aged 18 years and older, who died with cancer Denominator Criteria (Eligible Cases): 1) Patients aged ≥ 18 years at the start of the measurement period: (Start Date of the Measurement Period minus Date of Birth) ≥ 18 years AND 2) At least two outpatient encounters that meet the following criteria: 2a) Place of Service: 02, 05, 07, 10, 11, 19, 22, 49, 50, 71, 72 AND 2b) Professional Service code: 98000, 98001, 98002, 98003, 98004, 98005, 98006, 98007, 98008, 98009, 98010, 98011, 98012, 98013, 98014, 98015, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99242, 99243, 99244, 99245, 99495, 99496, 99441, 99442, 99443 (NOTE: Encounters coded with telehealth modifier GQ, GT, or 95 are allowed for both visits.) AND 2c) Service Date <during Measurement Period> AND 2d) Diagnosis code for Cancer (See tab “CancerDx” in “EOLMeasures_Coding”) AND 3) Date of death <during Measurement Period> Guidance: For physician/group reporting, attribution of patients to an oncology practice is based on the presence of at least two outpatient visit claims for the patient with that practice. The two outpatient encounters required in the denominator are outpatient visits that occur on different calendar days. To be eligible in the denominator, patients must have continuous coverage during the measurement period. A cancer diagnosis code must appear within the top 3 diagnosis positions on an outpatient visit claim that meets the denominator encounter requirement.
Denominator Exclusions:	None

Numerator:	Patients who had more than one emergency department and/or observation visit in the last 30 days of life Numerator Criteria: At least two Emergency Department and/or observation visits that meet the following criteria: [Revenue codes for Emergency Department Visit: 0450- Emergency Room 0451- Emergency room - EMTALA emergency medical screening services 0452- Emergency room - ER beyond EMTALA screening 0456- Emergency room-urgent care 0459- Emergency room-other 0981- Emergency room Observation Visits: (0762-Observation hours OR 0760- General) AND - G0378- Hospital observation service, per hour (HCPCS) WITH - Unit of 8 or more AND Emergency Department or Observation Visit Admission Date <during Measurement Period> AND Emergency Department or Observation Visit Admission Date in the last 30 days of life: (Date of death minus Emergency Department or Observation Visit Admission Date) < 30 days NOTE: The intent of the measure is to count a scenario where patient starts in ED and transitions to observation as one (1) visit.
Denominator Exceptions:	Patients with more than one ED and/or observation visit in the last 30 days of life due to complications from 1) receipt or in process of receipt of bone marrow or peripheral blood stem cell transplant (transplant status) in the last 60 days of life, or 2) receipt or in process of receipt of CAR T cell therapy in the last 60 days of life Denominator Exceptions Criteria: Receipt or in process of receipt of bone marrow or peripheral blood stem cell transplant Code: (See tab “BoneMarrowStemCellTransplant” in “EOLMeasures_Coding” file) AND Service/Procedure Date or Claim from Date (for ICD-10-CM transplant status code) AND (Date of death minus Service/Procedure Date or Claim from Date) < 60 days

	OR Receipt or in process of receipt of CAR T cell therapy Code: (See tab “CARCTx” in “EOLMeasures_Coding” file) AND Service/Procedure Date AND (Date of death minus Service/Procedure Date) < 60 days
Interpretation of Score:	Better quality is associated with a lower score
Risk Adjustment:	None

COPYRIGHT:

The Measure is not a clinical guideline, does not establish a standard of medical care, and has not been tested for all potential applications.

The Measure, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measure for commercial gain, or incorporation of the Measure into a product or service that is sold, licensed or distributed for commercial gain.

Commercial uses of the Measure require a license agreement between the user and American Society of Clinical Oncology (ASCO) and prior written approval of ASCO. Contact measurement@asco.org for licensing this measure. Neither ASCO, nor its members shall be responsible for any use of the Measure.

ASCO encourages use of the Measure by other health care professionals, where appropriate.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.

©2026 American Society of Clinical Oncology All Rights Reserved.

Limited proprietary coding is contained in the measure specifications for convenience. A license agreement must be entered prior to a third party’s use of Current Procedural Terminology (CPT®) or other proprietary code sets contained in the Measures. Any other use of CPT or other coding by the third party is strictly prohibited. ASCO and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

CPT® contained in this Measure specifications is copyright 2004-2026 American Medical Association. LOINC® copyright 2004-2026 Regenstreif Institute, Inc. SNOMED CLINICAL TERMS (SNOMED CT®) copyright 2004-2026 The International Health Terminology Standards Development Organisation (IHTSDO). ICD-10 is copyright 2024-2026 World Health Organization. All Rights Reserved.